arrow_back Trending Legislation
Share share

Faster Access to Foreign-Approved Drugs and Medical Devices

This act aims to speed up access to drugs, biological products, and medical devices in the U.S. that are already approved for marketing in other countries. This means citizens could get quicker access to new, potentially life-saving treatments available abroad, provided they meet strict safety requirements.
Key points
Allows for faster U.S. market approval of drugs and medical devices already legally sold in select countries, such as the United Kingdom.
Requires that these products address a public health or unmet medical need in the United States.
The FDA will still assess the safety and effectiveness of these products, with the power to deny approval or require additional post-market studies.
Congress has the ability to disapprove an FDA decision to deny a product, providing an additional layer of oversight.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2023
Print number: HR 3532
Sponsor: Rep. Roy, Chip [R-TX-21]
Process start date: 2023-05-18
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Faster Access to Foreign-Approved Drugs and Medical Devices

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3532.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-05-18.

What are the main provisions?

Key points include:

  • Allows for faster U.S. market approval of drugs and medical devices already legally sold in select countries, such as the United Kingdom.
  • Requires that these products address a public health or unmet medical need in the United States.
  • The FDA will still assess the safety and effectiveness of these products, with the power to deny approval or require additional post-market studies.
  • Congress has the ability to disapprove an FDA decision to deny a product, providing an additional layer of oversight.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Roy, Chip [R-TX-21].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 3532

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health